Clinical Trial Update: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

A Phase Ib safety study of Selinexor (KPT-330) in combination with standard chemotherapy or immunotherapy agents for patients with advanced malignancies was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• Selinexor (KPT-330) (selinexor)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Status: TERMINATED